Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib - Wikidata - thesis-toulmin - TriplyDB

Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib

Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib

http://www.wikidata.org/entity/Q34317307

about

Spotlight on ixazomib: potential in the treatment of multiple myeloma Enhanced brain delivery of lamotrigine with Pluronic(®) P123-based nanocarrier Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1 Enantioselective Addition of Bromonitromethane to Aliphatic N-Boc Aldimines Using a Homogeneous Bifunctional Chiral Organocatalyst.Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.(Immuno)proteasomes as therapeutic target in acute leukemia.Positioning of proteasome inhibitors in therapy of solid malignancies.

P2860

Q26774440-EFA9A168-3DED-4911-B0EC-091670C26AB5 Q34075276-C856AD5C-C638-416C-B73A-D1EC0AA2EFE3 Q35005087-26E5554A-1C41-43D5-A91E-5A32FC62B5C7 Q36186214-F036CFFB-36C8-4242-8937-B3C9C9742277 Q36717999-75AD4BD2-ED85-41B9-AFB4-86894E1D3897 Q36728394-907D35C7-DDE3-4831-B3F6-348C45688C32 Q37396016-FC8BBEEF-A789-48CD-8032-CDC97B07FA3E Q38683263-D3880BC1-C611-4220-A4E3-5C787EFE0219 Q38986185-0B72B8E8-857C-41E3-BD33-207BC62D98E1 Q41620033-E399DE3E-A6F0-43A6-B0F2-7E936F2430B3 Q47115348-61607F3E-2FC5-4C54-B5CF-1DDAED31BCE0 Q47131929-5824A886-3DE8-4138-8073-78934551EF5B Q47353792-F5CF21CD-0525-49E8-B4C5-8A92EA445E72

P2860

Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib

http://www.wikidata.org/entity/Q34317307

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Development of peptide-based r ...... ated resistance to carfilzomib

@ast

Development of peptide-based r ...... ated resistance to carfilzomib

@en

Development of peptide-based r ...... ated resistance to carfilzomib

@nl

type

label

Development of peptide-based r ...... ated resistance to carfilzomib

@ast

Development of peptide-based r ...... ated resistance to carfilzomib

@en

Development of peptide-based r ...... ated resistance to carfilzomib

@nl

prefLabel

Development of peptide-based r ...... ated resistance to carfilzomib

@ast

Development of peptide-based r ...... ated resistance to carfilzomib

@en

Development of peptide-based r ...... ated resistance to carfilzomib

@nl

P1433

Q34317307-D15618A2-5726-4C0D-B62B-65D80211F34F

P1476

Q34317307-176F9CDD-84F7-4882-A31E-B399F09D90FD

P2093

Q34317307-427FA0E4-4FE4-45D1-B8B5-E5D6DA456D80

Q34317307-66F54161-7BD8-44C7-92CD-8B26C5B630B1

Q34317307-7C8504BE-6071-4CEE-8F56-36C970EE408D

Q34317307-9556782A-07CB-42E4-9409-18EE69C6B5BF

Q34317307-A97214D0-76D5-4C80-9AD0-BB9C008D8D8A

Q34317307-EB15186B-54B3-4632-A13D-EC24C5320F0C

Q34317307-F12329BA-0055-420F-9990-EB16747D653B

P2860

Q34317307-2596A27B-5207-4FD9-A45C-97DD3BC48BFA

Q34317307-2C54AD60-8B1A-4725-AA82-B0FBE44AA53B

Q34317307-2DB8A828-8208-4384-86C0-DF9A0C501C60

Q34317307-3305D2D4-BF6A-45F7-A2B2-09712A0C0E76

Q34317307-3A1CD239-B38A-4F3D-B1A2-5821958307F9

Q34317307-3F285500-35D1-4126-A824-7C0E4F5986AD

Q34317307-435237B7-B9DB-43D9-80FD-3E76458141FA

Q34317307-4622B73A-D186-4ECA-8D23-8C44EC45BA05

Q34317307-53FAA5E0-B26C-46FA-8FE6-6E28D90FE023

Q34317307-60903D62-E217-4B93-AC20-64EBD534125E

P304

Q34317307-3218CBC9-67BF-4FF3-88CF-BC1071D183EC

P31

Q34317307-07AE176E-9F60-4E1E-88DD-9CFB3A89E449

P356

Q34317307-33BF3722-5695-4D80-BF72-50A6B0EFA0E1

P407

Q34317307-CFF9B4EC-8967-4659-B5DD-BF679D17667D

P433

Q34317307-6E184D28-77C3-46AB-BD2E-962953D1EC84

P478

Q34317307-8A7890CE-286E-42B9-82BD-E6C3FD4AC13A

P50

Q34317307-E9AE53AB-AFCC-4B5A-B227-B3947BD8EB0D

P577

Q34317307-09280B6E-0123-442B-AA71-D8AA127948E4

P5875

Q34317307-F166ED26-E201-45F5-A434-390527BC9900

P698

Q34317307-06C2F338-EFAA-4083-8610-F8E86BB73504

P921

Q34317307-43695109-7C46-439D-8655-2EF28E15F266

P932

Q34317307-DB1E372E-681A-4A2F-97AB-5120026E7145

P356

P1433

Molecular Pharmaceutics

P1476

Development of peptide-based r ...... ated resistance to carfilzomib

@en

P2093

Do-Min Lee

http://www.w3.org/2001/XMLSchema#string

Donghern Kim

http://www.w3.org/2001/XMLSchema#string

Eun Ryoung Jang

http://www.w3.org/2001/XMLSchema#string

Kyung Bo Kim

http://www.w3.org/2001/XMLSchema#string

Kyunghwa Kim

http://www.w3.org/2001/XMLSchema#string

Lin Ao

http://www.w3.org/2001/XMLSchema#string

Ying Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding

Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein

Lack of proteasome active site allostery as revealed by subunit-specific inhibitors.

Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.

The ubiquitin system, disease, and drug discovery.

p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.

The development of proteasome inhibitors as anticancer drugs.

P304

2197-2205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/MP300044B

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228069575

http://www.w3.org/2001/XMLSchema#string

P698

22734651

http://www.w3.org/2001/XMLSchema#string

P921

P932

3473138

http://www.w3.org/2001/XMLSchema#string